Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | FGFR1 |
Variant | R576W |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | FGFR1 R576W lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). R576W has been identified in sequencing studies (PMID: 16186508, PMID: 27149842), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Mar 2024). |
Associated Drug Resistance | |
Category Variants Paths |
FGFR1 mutant FGFR1 R576W |
Transcript | NM_023110.3 |
gDNA | chr8:g.38415998G>A |
cDNA | c.1726C>T |
Protein | p.R576W |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_023110.2 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
XM_017013221.1 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
XM_006716304.1 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
XM_006716304.2 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
NM_023110.3 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
XM_006716303 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
XM_017013221 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
XM_006716303.3 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
XM_006716304 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
XM_017013221.2 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
NM_023110 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
XM_006716303.4 | chr8:g.38415998G>A | c.1726C>T | p.R576W | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR1 mutant | Advanced Solid Tumor | predicted - sensitive | Debio 1347 | Phase I | Actionable | In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297). | 30745300 |
FGFR1 mutant | Advanced Solid Tumor | predicted - sensitive | Erdafitinib | Case Reports/Case Series | Actionable | In a Phase II trial (MATCH), Balversa (erdafitinib) treatment resulted in an objective response rate of 16% (4/25), median progression-free survival of 3.6 months, and median overall survival of 11.0 months in patients with advanced solid tumors harboring FGFR1, FGFR2, or FGFR3 mutations or fusions (PMID: 38603650; NCT02465060). | 38603650 |
FGFR1 mutant | transitional cell carcinoma | predicted - sensitive | Erdafitinib | Phase II | Actionable | In a Phase II trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 42% (40/96, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (J Clin Oncol 36, 2018 (suppl; abstr 4503); NCT02365597). | detail... |
FGFR1 mutant | Advanced Solid Tumor | sensitive | Pemigatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to Pemazyre (pemigatinib) in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771). | detail... |
FGFR1 mutant | Advanced Solid Tumor | predicted - sensitive | ICP-192 | Phase I | Actionable | In a Phase I trial, ICP-192 (gunagratinib) was well-tolerated, and resulted in an overall response rate or 33.3% (4/12, 1 complete response, 3 partial response) and a disease control rate of 91.7% (11/12) in patients with advanced solid tumors harboring FGF/FGFR gene aberrations (J Clin Oncol 39, 2021 (suppl 15; abstr 4092); NCT03758664). | detail... |